Agree with the primacy of results: delivering successful RCT's and approvals etc. I think they have done a reasonable job so far in this regard, except perhaps for the bronchiectasis trial. I don't agree with Postman that the cash position and burn is a major factor, especially when bronchitol is close to market in both Aust/ Europe. The study results for CF were impressive and undeniable from a clinical viewpoint.
price, page-29
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.8¢ |
Change
-0.002(6.67%) |
Mkt cap ! $36.13M | |||
| Open | High | Low | Value | Volume |
| 3.0¢ | 3.0¢ | 2.8¢ | $208.0K | 7.159M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 1443885 | 2.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.9¢ | 1091321 | 2 |
View Market Depth
| Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
| SNT (ASX) Chart |